# A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

> **NCT03574779** · PHASE2 · COMPLETED · sponsor: **Tesaro, Inc.** · enrollment: 77 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Niraparib
- **BIOLOGICAL:** TSR-042
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03574779
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-15
- **Primary completion:** 2024-06-28
- **Final completion:** 2025-03-31
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574779, "A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03574779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*